scispace - formally typeset
Search or ask a question
Topic

Pertuzumab

About: Pertuzumab is a research topic. Over the lifetime, 1453 publications have been published within this topic receiving 73219 citations. The topic is also known as: 2C4 Antibody & MOAB 2C4.


Papers
More filters
Journal ArticleDOI
TL;DR: Pertuzumab is a humanized antibody that targets and binds HER2 and has demonstrated significant activity when combined with trastuzumAB against trastudumab-resistant and -sensitive disease.
Abstract: Approximately 15% of primary breast cancers have amplification/overexpression of the cell surface receptor HER2. Despite the major improvements in survival achieved by the use of adjuvant trastuzumab, many of these patients still develop metastatic disease, and other patients with HER2 overexpressing breast cancer have overt metastases at first diagnosis. There remains therefore a pressing medical need to identify better therapies for these patients. Pertuzumab is a humanized antibody that targets and binds HER2. Although only modestly active against breast cancer when used as a single agent, pertuzumab has demonstrated significant activity when combined with trastuzumab against trastuzumab-resistant and -sensitive disease. Multiple clinical trials are underway to define the optimal use of pertuzumab (combined with either trastuzumab or trastuzumab-DM1) together with a range of cytotoxic agents or endocrine therapy in multiple settings of HER2-overexpressing breast cancer. This article summarizes the use of pertuzumab in the metastatic disease setting.

8 citations

Journal ArticleDOI
TL;DR: A statistically significant and clinically relevant benefit is reported for the pertuzumab-based treatment of metastatic or locally recurrent non resecable HER2-positive breast cancers not previously treated by chemotherapy or Her2-inhibitors in the metastatic setting.
Abstract: Fifteen to 20% of breast cancers display HER2 amplification Many therapeutic successes have been obtained for this subtype in the last decade since trastuzumab approval for metastatic and localized diseases Pertuzumab, a new anti-HER2 antibody, has been approved in 2013 by the European Medicine Agency This drug can be used in combination with trastuzumab and docetaxel for the first line treatment of metastatic or locally recurrent non resecable HER2-positive breast cancers not previously treated by chemotherapy or HER2-inhibitors in the metastatic setting This approval has been done after the CLEOPATRA trial results This was a randomized, double-blind, multicentre, phase III trial evaluating the standard treatment (trastuzumab plus docetaxel) associated to pertuzumab or placebo The authors have reported a statistically significant and clinically relevant benefit for the pertuzumab-based treatment Median progression-free survival was 184 for the pertuzumab arm versus 125 months for the control group (p<0001) They also observed benefits concerning the secondary endpoints: overall response rate and overall survival Patients receiving pertuzumab presented more frequent diarrhea and febrile neutropenia but no increase in cardiac events This drug has already been evaluated in the neoadjuvant setting with a FDA approval recently obtained Its use in the adjuvant setting is under evaluation

8 citations

Journal ArticleDOI
TL;DR: Pertuzumab, a recombinant human-ized monoclonal antibody binding to the HER2 dimerization domain, prevents dimerisation of HER2 with other HER receptors (HER3, HER1, and HER4), especially with HER3.
Abstract: positive metastatic breast cancer receiving first-line therapy, the addition of pertuzumab to docetaxel plus trastuzumab was associated with a 6-month increase in progression-free survival. Pertuzumab, a recombinant human-ized monoclonal antibody binding to the HER2 dimerization domain, prevents dimerization of HER2 with other HER receptors (HER3, HER1, and HER4), especially with HER3.

8 citations

01 Jan 2015
TL;DR: The current pharmacotherapeutic recommendations for targeted therapies for the treatment of breast cancer are based on evidence of therapeutic efficacy and cost effectiveness and their application in therapeutic practice in Bulgaria is necessary to ensure patient access to effective therapies within the limited public funds.
Abstract: PURPOSE The purpose of this study was to determine the direct costs of targeted cancer therapies for the treatment of breast cancer, calculating the effectiveness of the additional costs (ICER) and the cost of life years gained (LYG), using data from randomized clinical trials cited in the summary of product characteristics (SPC) of medicinal products approved for use under the centralized procedure. METHODS Data from the SPC and clinical trials was analyzed. ICER and LYG of the medicinal therapies were compared using data from Phase III clinical trials cited in the Summary of product characteristics. The perspective of the payer was adopted. RESULTS The SPCs of five drugs were analyzed. Targeted therapies were compared to placebo or to best supportive care (BSC) in some of them, while in others monoclonal antibodies (mAbs) and tyrosine kinase inhibitors were compared to existing drug therapies. Cost-effectiveness of each therapy was calculated. The value of ICER was between 56 470 Bulgarian Levs/LYG and 879 480 Bulgarian Levs/LYG. CONCLUSION The current pharmacotherapeutic recommendations for targeted therapies for the treatment of breast cancer are based on evidence of therapeutic efficacy and cost effectiveness. Their application in therapeutic practice in Bulgaria is necessary to ensure patient access to effective therapies within the limited public funds.

8 citations


Network Information
Related Topics (5)
Breast cancer
214.3K papers, 6.4M citations
89% related
Cancer
339.6K papers, 10.9M citations
87% related
Colorectal cancer
71.1K papers, 2.2M citations
84% related
Metastasis
103.6K papers, 3.4M citations
84% related
Carcinogenesis
60.3K papers, 3.1M citations
83% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
2023372
2022307
2021158
2020144
2019143
2018130